Styles Christine T, Bazot Quentin, Parker Gillian A, White Robert E, Paschos Kostas, Allday Martin J
Molecular Virology, Department of Medicine, Imperial College London, London, United Kingdom.
PLoS Biol. 2017 Aug 3;15(8):e2001992. doi: 10.1371/journal.pbio.2001992. eCollection 2017 Aug.
Mature human B cells infected by Epstein-Barr virus (EBV) become activated, grow, and proliferate. If the cells are infected ex vivo, they are transformed into continuously proliferating lymphoblastoid cell lines (LCLs) that carry EBV DNA as extra-chromosomal episomes, express 9 latency-associated EBV proteins, and phenotypically resemble antigen-activated B-blasts. In vivo similar B-blasts can differentiate to become memory B cells (MBC), in which EBV persistence is established. Three related latency-associated viral proteins EBNA3A, EBNA3B, and EBNA3C are transcription factors that regulate a multitude of cellular genes. EBNA3B is not necessary to establish LCLs, but EBNA3A and EBNA3C are required to sustain proliferation, in part, by repressing the expression of tumour suppressor genes. Here we show, using EBV-recombinants in which both EBNA3A and EBNA3C can be conditionally inactivated or using virus completely lacking the EBNA3 gene locus, that-after a phase of rapid proliferation-infected primary B cells express elevated levels of factors associated with plasma cell (PC) differentiation. These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the master transcriptional regulator of PC differentiation B lymphocyte-induced maturation protein-1 (BLIMP-1), and the cell surface antigens CD38 and CD138/Syndecan-1. Chromatin immunoprecipitation sequencing (ChIP-seq) and chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) indicate that in LCLs inhibition of CDKN2C (p18INK4c) and PRDM1 (BLIMP-1) transcription results from direct binding of EBNA3A and EBNA3C to regulatory elements at these loci, producing stable reprogramming. Consistent with the binding of EBNA3A and/or EBNA3C leading to irreversible epigenetic changes, cells become committed to a B-blast fate <12 days post-infection and are unable to de-repress p18INK4c or BLIMP-1-in either newly infected cells or conditional LCLs-by inactivating EBNA3A and EBNA3C. In vitro, about 20 days after infection with EBV lacking functional EBNA3A and EBNA3C, cells develop a PC-like phenotype. Together, these data suggest that EBNA3A and EBNA3C have evolved to prevent differentiation to PCs after infection by EBV, thus favouring long-term latency in MBC and asymptomatic persistence.
感染爱泼斯坦-巴尔病毒(EBV)的成熟人类B细胞会被激活、生长并增殖。如果这些细胞在体外被感染,它们会转化为持续增殖的淋巴母细胞系(LCLs),这些细胞系将EBV DNA作为染色体外附加体携带,表达9种与潜伏相关的EBV蛋白,并且在表型上类似于抗原激活的B母细胞。在体内,类似的B母细胞可以分化成为记忆B细胞(MBC),EBV在其中建立持续存在状态。三种相关的与潜伏相关的病毒蛋白EBNA3A、EBNA3B和EBNA3C是调节众多细胞基因的转录因子。EBNA3B对于建立LCLs并非必需,但EBNA3A和EBNA3C是维持增殖所必需的,部分原因是它们通过抑制肿瘤抑制基因的表达来实现这一点。在这里,我们展示了使用EBV重组体(其中EBNA3A和EBNA3C都可以被条件性失活)或使用完全缺乏EBNA3基因座的病毒,在快速增殖阶段之后,被感染的原代B细胞会表达与浆细胞(PC)分化相关的因子的升高水平。这些因子包括细胞周期蛋白依赖性激酶抑制剂(CDKI)p18INK4c、PC分化的主要转录调节因子B淋巴细胞诱导成熟蛋白-1(BLIMP-1)以及细胞表面抗原CD38和CD138/多配体蛋白聚糖-1。染色质免疫沉淀测序(ChIP-seq)和染色质免疫沉淀定量PCR(ChIP-qPCR)表明,在LCLs中,CDKN2C(p18INK4c)和PRDM1(BLIMP-1)转录的抑制是由于EBNA3A和EBNA3C直接结合到这些基因座的调控元件上,从而产生稳定的重编程。与EBNA3A和/或EBNA3C的结合导致不可逆的表观遗传变化一致,在感染后<12天,细胞就注定要成为B母细胞命运,并且无论是在新感染的细胞还是条件性LCLs中,通过使EBNA3A和EBNA3C失活,都无法去抑制p18INK4c或BLIMP-1。在体外,在用缺乏功能性EBNA3A和EBNA3C的EBV感染约20天后,细胞会发展出类似PC的表型。总之,这些数据表明EBNA3A和EBNA3C已经进化到能够防止EBV感染后分化为PC,从而有利于MBC中的长期潜伏和无症状持续存在。